Described herein are apparatus and methods for detecting substances of abuse or other analytes in liquids. For example, the apparatus and methods described herein can be used for real-time detection of analytes, such as substances of abuse. The methods comprise providing a detection area comprising a chromatographic membrane capable of receiving the liquid and allowing for migration of the liquid, the chromatographic membrane comprising an anti-analyte antibody-particle conjugate, an analyte-conjugate protein at a test line; exposing at least the first location of the apparatus to the liquid; and determining whether an interaction between the analyte-conjugate protein and the liquid occurs to detect the presence of the analyte. The chromatographic membrane may further comprise an anti-species antibody at a control line. Specific buffers are disclosed, and these buffers may be used in the preparation of the apparatus to overcome challenges associated with miniaturization and challenges associated with exposure to beverages.

Described herein are apparatus and methods for detecting substances of abuse or other analytes in liquids. For example, the apparatus and methods described herein can be used for real-time detection of analytes, such as substances of abuse. The methods comprise providing a detection area comprising a chromatographic membrane capable of receiving the liquid and allowing for migration of the liquid, the chromatographic membrane comprising an anti-analyte antibody-particle conjugate, an analyte-conjugate protein at a test line; exposing at least the first location of the apparatus to the liquid; and determining whether an interaction between the analyte-conjugate protein and the liquid occurs to detect the presence of the analyte. The chromatographic membrane may further comprise an anti-species antibody at a control line. Specific buffers are disclosed, and these buffers may be used in the preparation of the apparatus to overcome challenges associated with miniaturization and challenges associated with exposure to beverages.

Described herein are a wearable apparatus and methods for detecting the presence of a targeted substance in a liquid. For example, the wearable apparatus can be a fingernail that detects illicit drugs in a beverage. The wearable apparatus comprises a detection layer comprising an indicator that is configured to display a signal upon the detection of an interaction with the targeted substance. In some examples, the wearable apparatus can include a lateral flow assay.

This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present of secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provide metabolic signatures of autism, which can be used to provide a diagnosis thereof.

Double caged GABA compounds and compositions including the same are described. Methods of synthesizing and using double caged GABA compounds are provided.

The invention refers to BTBD9 binders and gephyrin binders for medical use and in particular an artemisinin compound of general formula I for use in the treatment of a diabetes patient, as well as a method of identifying suitable lead candidates.

This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present of secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provide metabolic signatures of autism, which can be used to provide a diagnosis thereof.

Provided herein are methods for selecting a subject with a seizure disorder for treatment, as well as methods of treating the subject, determining the efficacy of the treatment, and adjusting the treatment dosage and frequency. In some aspects, provided herein are methods of treating seizures in a subject by administering to the subject a composition comprising bacteria of the Akkermansia (Akk) and Parabacteroides (Pb) genera.

Described herein are compositions and methods for bioluminescent analyte detection. In some embodiments, a recombinant bioluminescent polypeptide sensor is disclosed comprising a luminescent signaling domain, an analyte binding domain, and one or more peptide linkers, wherein the luminescent signaling domain is oriented in relation to the analyte binding domain such that binding of an analyte to the analyte binding domain induces a conformational change in the luminescent signaling domain to generate a luminescent signal.